Alto Neuroscience (NYSE:ANRO) Trading 9.1% Higher – Here’s Why

Alto Neuroscience, Inc. (NYSE:ANRO)’s stock price shot up 9.1% during trading on Tuesday . The stock traded as high as $22.00 and last traded at $21.7950. 102,530 shares were traded during trading, a decline of 56% from the average session volume of 234,185 shares. The stock had previously closed at $19.98.

Wall Street Analyst Weigh In

Several analysts have issued reports on ANRO shares. Wall Street Zen lowered shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Jefferies Financial Group reiterated a “buy” rating and issued a $35.00 target price on shares of Alto Neuroscience in a research note on Monday, March 16th. Chardan Capital reissued a “buy” rating and set a $30.00 target price on shares of Alto Neuroscience in a research report on Tuesday, March 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Finally, Wedbush upped their price target on Alto Neuroscience from $13.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, March 17th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $34.33.

Alto Neuroscience Trading Up 13.3%

The company has a debt-to-equity ratio of 0.12, a current ratio of 15.69 and a quick ratio of 15.69. The business’s 50 day simple moving average is $18.87 and its 200 day simple moving average is $14.44. The stock has a market cap of $723.32 million, a P/E ratio of -10.35 and a beta of 2.51.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.11. On average, analysts expect that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Vestal Point Capital LP boosted its stake in shares of Alto Neuroscience by 161.6% in the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock valued at $44,233,000 after purchasing an additional 1,535,000 shares in the last quarter. Commodore Capital LP acquired a new stake in shares of Alto Neuroscience during the 4th quarter worth about $32,453,000. Perceptive Advisors LLC lifted its holdings in Alto Neuroscience by 1,048.5% during the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after purchasing an additional 1,629,027 shares during the last quarter. Armistice Capital LLC boosted its position in Alto Neuroscience by 0.7% in the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock valued at $6,577,000 after buying an additional 12,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Alto Neuroscience by 1.9% in the third quarter. Vanguard Group Inc. now owns 1,105,407 shares of the company’s stock valued at $4,444,000 after buying an additional 20,702 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.